CPL-410-005 / Celon Pharma - LARVOL DELTA

Biological Basis for the Development of CPL410005 as an Antibody-Drug Conjugate (EACR 2025) - "CPL410005's potent UBA1 inhibition utilized in the form of ADC technology enhances tumor selectivity and reduces systemic toxicity. These findings support further preclinical development of HER2-targeted UBA1 inhibitors as a novel therapeutic strategy for HER2-positive cancers. Project co-financed by NCBR, POIR.01.02.00-00-0009/17"

Oncology • Targeted Protein Degradation

Design and development of an innovative, safe, and highly potent E1 ubiquitin-activating enzyme inhibitor CPL–410-005 conjugate in anticancer therapy"? (AACR-NCI-EORTC 2022) - "The therapeutic potential of this pathway has been validated by the clinical successes of bortezomib – the first proteasome inhibitor drug implemented in the therapy of multiple myeloma and mantle cell lymphoma...This implies enhanced safety by reducing off-target side effects compared to free CPL-410-005 and unconjugated CPL-410-005 derivatives...Presented results support further preclinical validation for the validation of anti-HER2-drug conjugates and ubiquitin-proteasome system inhibitors in cancer therapy. No"

Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Oncology • Solid Tumor